Insider Trading Alert - SAIC And 3 Others Traded By Insiders

Yesterday, July 3, 2013, 489 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $0.00 to $202,421,072.70.

Highlighted Stocks Traded by Insiders:

SAIC (SAI) - FREE Research Report

Baybrook Thomas G who is (Acting) Group President at SAIC INC bought 4,153 shares on June 28, 2013. Following this transaction, the (Acting) Group President owned 48,948 shares meaning that the stake was boosted by 9.27% with the 4,153 share acquisition.

Cordova France A who is Director at SAIC INC bought 3,039 shares on June 28, 2013. Following this transaction, the Director owned 44,430 shares meaning that the stake was boosted by 7.34% with the 3,039 share acquisition.

Craver Joseph W Iii who is Sector President at SAIC INC bought 4,998 shares on June 28, 2013. Following this transaction, the Sector President owned 146,016 shares meaning that the stake was boosted by 3.54% with the 4,998 share acquisition.

Cuff James E who is Executive Vice President at SAIC INC bought 20,475 shares on June 28, 2013. Following this transaction, the Executive Vice President owned 136,195 shares meaning that the stake was boosted by 17.69% with the 20,475 share acquisition.

Drummond Jere A who is Director at SAIC INC bought 2,488 shares on June 28, 2013. Following this transaction, the Director owned 75,652 shares meaning that the stake was boosted by 3.4% with the 2,488 share acquisition.

Frist Thomas F Iii who is Director at SAIC INC bought 591,139 shares on June 28, 2013. Following this transaction, the Director owned 631,365 shares meaning that the stake was boosted by 1469.54% with the 591,139 share acquisition.

Hamre John J who is Director at SAIC INC bought 11,711 shares on June 28, 2013. Following this transaction, the Director owned 104,255 shares meaning that the stake was boosted by 12.65% with the 11,711 share acquisition.

Hartley John Robert who is Senior VP and Controller at SAIC INC bought 2,700 shares on June 28, 2013. Following this transaction, the Senior VP and Controller owned 37,939 shares meaning that the stake was boosted by 7.66% with the 2,700 share acquisition.

James Deborah L who is Group President at SAIC INC bought 20,702 shares on June 28, 2013. Following this transaction, the Group President owned 170,375 shares meaning that the stake was boosted by 13.83% with the 20,702 share acquisition.

John Miriam E who is Director at SAIC INC bought 6,587 shares on June 28, 2013. Following this transaction, the Director owned 96,302 shares meaning that the stake was boosted by 7.34% with the 6,587 share acquisition.

Jones Anita K who is Director at SAIC INC bought 1,417 shares on June 28, 2013. Following this transaction, the Director owned 111,435 shares meaning that the stake was boosted by 1.29% with the 1,417 share acquisition.

Jumper John P who is CEO and President at SAIC INC bought 10,279 shares on June 28, 2013. Following this transaction, the CEO and President owned 180,345 shares meaning that the stake was boosted by 6.04% with the 10,279 share acquisition.

Keenan Brian F who is Executive Vice President at SAIC INC bought 19,287 shares on June 28, 2013. Following this transaction, the Executive Vice President owned 129,169 shares meaning that the stake was boosted by 17.55% with the 19,287 share acquisition.

Keene Nazzic S who is Group President at SAIC INC bought 754 shares on June 28, 2013. Following this transaction, the Group President owned 16,989 shares meaning that the stake was boosted by 4.64% with the 754 share acquisition.

Kraemer Harry M Jansen Jr who is Director at SAIC INC bought 243,151 shares on June 28, 2013. Following this transaction, the Director owned 389,267 shares meaning that the stake was boosted by 166.41% with the 243,151 share acquisition.

Maffeo Vincent A who is Executive VP & General Counsel at SAIC INC bought 2,092 shares on June 28, 2013. Following this transaction, the Executive VP & General Counsel owned 44,323 shares meaning that the stake was boosted by 4.95% with the 2,092 share acquisition.

Moraco Anthony J who is Sector President at SAIC INC bought 11,457 shares on June 28, 2013. Following this transaction, the Sector President owned 77,059 shares meaning that the stake was boosted by 17.47% with the 11,457 share acquisition.

Nussdorf Lawrence C who is Director at SAIC INC bought 495 shares on June 28, 2013. Following this transaction, the Director owned 32,496 shares meaning that the stake was boosted by 1.55% with the 495 share acquisition.

Sanderson Edward J Jr who is Director at SAIC INC bought 1,503 shares on June 28, 2013. Following this transaction, the Director owned 110,593 shares meaning that the stake was boosted by 1.38% with the 1,503 share acquisition.

Shea K Stuart who is Chief Operating Officer at SAIC INC bought 17,698 shares on June 28, 2013. Following this transaction, the Chief Operating Officer owned 147,204 shares meaning that the stake was boosted by 13.67% with the 17,698 share acquisition.

Sopp Mark W who is Executive VP and CFO at SAIC INC bought 6,441 shares on June 28, 2013. Following this transaction, the Executive VP and CFO owned 124,477 shares meaning that the stake was boosted by 5.46% with the 6,441 share acquisition.

The shares most recently traded at $13.84, down $0.09, or 0.65% since the insider transactions.

The average volume for SAIC has been 3.7 million shares per day over the past 30 days. SAIC has a market cap of $4.8 billion and is part of the technology sector and computer software & services industry. Shares are up 23.06% year to date as of the close of trading on Tuesday.

SAIC, Inc. provides scientific, engineering, systems integration, and technical services and solutions in the areas of defense, health, energy, infrastructure, intelligence, surveillance, reconnaissance, and cybersecurity to agencies of the U.S. The stock currently has a dividend yield of 3.45%. The company has a P/E ratio of 9.8. Currently there are 2 analysts that rate SAIC a buy, 2 analysts rate it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on SAI - FREE

TheStreet Quant Ratings rates SAIC as a buy. The company's strengths can be seen in multiple areas, such as its reasonable valuation levels, good cash flow from operations, increase in stock price during the past year, notable return on equity and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full SAIC Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Ironwood Pharmaceuticals (IRWD) - FREE Research Report

Conrades George H who is Director at IRONWOOD PHARMA bought 1.1 million shares on June 28, 2013. Following this transaction, the Director owned 1.1 million shares meaning that the stake was boosted by 11567.66% with the 1.1 million share acquisition.

Roberts Bryan E who is Director at IRONWOOD PHARMA bought 6.7 million shares at $0.83 per share for a total value of $2,492.43 on June 28, 2013. Following this transaction, the Director owned 6.7 million shares meaning that the stake was boosted by 44444.98% with the 6.7 million share acquisition.

Shaw David Evans who is Director at IRONWOOD PHARMA bought 329,400 shares on June 28, 2013. Following this transaction, the Director owned 383,495 shares meaning that the stake was boosted by 608.93% with the 329,400 share acquisition.

The shares most recently traded at $10.00, up $0.02, or 0.2% since the insider transactions.

The average volume for Ironwood Pharmaceuticals has been 1.3 million shares per day over the past 30 days. Ironwood Pharmaceuticals has a market cap of $958.9 million and is part of the health care sector and health services industry. Shares are down 7.58% year to date as of the close of trading on Tuesday.

Ironwood Pharmaceuticals, Inc., an entrepreneurial pharmaceutical company, discovers, develops, and commercializes human therapeutic products. Currently there are 3 analysts that rate Ironwood Pharmaceuticals a buy, 2 analysts rate it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on IRWD - FREE

TheStreet Quant Ratings rates Ironwood Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, disappointing return on equity, weak operating cash flow and generally high debt management risk. Get the full Ironwood Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Colonial Properties (CLP) - FREE Research Report

Bailey Carl F who is Trustee at COLONIAL PPTYS bought 3,975 shares at $12.06 per share for a total value of $71,757.00 on June 28, 2013. Following this transaction, the Trustee owned 175,757 shares meaning that the stake was boosted by 2.31% with the 3,975 share acquisition.

Crawford Edwin M who is Trustee at COLONIAL PPTYS bought 2,510 shares at $24.12 per share for a total value of $60,541.20 on June 28, 2013. Following this transaction, the Trustee owned 16,475 shares meaning that the stake was boosted by 17.97% with the 2,510 share acquisition.

Gorrie M Miller who is Trustee at COLONIAL PPTYS bought 698,370 shares at $4.82 per share for a total value of $38,857.32 on June 28, 2013. Following this transaction, the Trustee owned 995,775 shares meaning that the stake was boosted by 234.82% with the 698,370 share acquisition.

Johnson William M who is Trustee at COLONIAL PPTYS bought 179,735 shares at $12.06 per share for a total value of $32,200.20 on June 28, 2013. Following this transaction, the Trustee owned 225,218 shares meaning that the stake was boosted by 395.17% with the 179,735 share acquisition.

Meisler Herbert A who is Trustee at COLONIAL PPTYS bought 1,350 shares at $24.12 per share for a total value of $32,562.00 on June 28, 2013. Following this transaction, the Trustee owned 269,948 shares meaning that the stake was boosted by 0.5% with the 1,350 share acquisition.

Nielsen Claude B who is Trustee at COLONIAL PPTYS bought 8,958 shares at $12.06 per share for a total value of $47,950.56 on June 28, 2013. Following this transaction, the Trustee owned 62,348 shares meaning that the stake was boosted by 16.78% with the 8,958 share acquisition.

Ripps Harold W who is Trustee at COLONIAL PPTYS bought 51,509 shares at $12.06 per share for a total value of $36,397.08 on June 28, 2013. Following this transaction, the Trustee owned 415,605 shares meaning that the stake was boosted by 14.15% with the 51,509 share acquisition.

Spiegel John W who is Trustee at COLONIAL PPTYS bought 3,091 shares at $24.12 per share for a total value of $74,554.92 on June 28, 2013. Following this transaction, the Trustee owned 88,623 shares meaning that the stake was boosted by 3.61% with the 3,091 share acquisition.

The shares most recently traded at $24.01, down $0.28, or 1.15% since the insider transactions.

The average volume for Colonial Properties has been 1.2 million shares per day over the past 30 days. Colonial Properties has a market cap of $2.1 billion and is part of the financial sector and real estate industry. Shares are up 12.4% year to date as of the close of trading on Tuesday.

Colonial Properties Trust is a real estate investment trust (REIT). The firm engages in the acquisition, development, ownership, management, and leasing of commercial real estate properties. It invests in the public equity and real estate markets of the United States. The stock currently has a dividend yield of 3.5%. Currently there is 1 analyst that rates Colonial Properties a buy, 1 analyst rates it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CLP - FREE

TheStreet Quant Ratings rates Colonial Properties as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, good cash flow from operations and growth in earnings per share. However, as a counter to these strengths, we also find weaknesses including disappointing return on equity and poor profit margins. Get the full Colonial Properties Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Everest Re Group (RE) - FREE Research Report

Amore John J who is Director at EVEREST RE bought 145 shares at $129.21 per share for a total value of $18,735.45 on July 1, 2013. Following this transaction, the Director owned 3,840 shares meaning that the stake was boosted by 3.92% with the 145 share acquisition.

The shares most recently traded at $126.45, up $0.09, or 0.07% since the insider transaction. Historical insider transactions for Everest Re Group go as follows:

  • 4-Week # shares sold: 800
  • 12-Week # shares sold: 5,128
  • 24-Week # shares sold: 10,128

The average volume for Everest Re Group has been 402,100 shares per day over the past 30 days. Everest Re Group has a market cap of $6.4 billion and is part of the financial sector and insurance industry. Shares are up 14.93% year to date as of the close of trading on Tuesday.

Everest Re Group, Ltd., through its subsidiaries, underwrites reinsurance and insurance products. It operates in four segments: U.S. Reinsurance, Insurance, International, and Bermuda. The U.S. The stock currently has a dividend yield of 1.49%. The company has a P/E ratio of 7.3. Currently there are 2 analysts that rate Everest Re Group a buy, no analysts rate it a sell, and 7 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on RE - FREE

TheStreet Quant Ratings rates Everest Re Group as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income, revenue growth and largely solid financial position with reasonable debt levels by most measures. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Everest Re Group Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Data for this article provided by Zacks Investment Research

null

More from Markets

Three Big Factors That Rocked the Stock Market Tuesday

Three Big Factors That Rocked the Stock Market Tuesday

Dow Tumbles Over 400 Points; S&P 500 and Nasdaq Also Finish Lower

Dow Tumbles Over 400 Points; S&P 500 and Nasdaq Also Finish Lower

Caterpillar Bulldozes Industrial Sector With Bad News on Earnings Call

Caterpillar Bulldozes Industrial Sector With Bad News on Earnings Call

Jim Cramer: If You're Afraid of the 10-Year Yield, Go to Cash

Jim Cramer: If You're Afraid of the 10-Year Yield, Go to Cash

Eli Lilly CEO Expresses Confidence in New Rheumatoid Arthritis Drug

Eli Lilly CEO Expresses Confidence in New Rheumatoid Arthritis Drug